Leerink analyst Faisal Khurshid initiated coverage of Geron with an Outperform rating and $7 price target, and named it a Top Pick in the Emerging Immunology sector. The firm likes Geron for 2025 as it believes Rytelo has blockbuster potential in lower-risk myelodysplastic syndrome and thinks quarterly revenues over 2025 will begin to show this.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GERN: